\
&
Contact us
\
&
Contact us
This was 5 years ago
LocationOnline
The FET BRIEFING - Bridging the FET Innovation Gap project is a Coordination and Support Action (CSA) that received funding under the Horizon 2020 call FETOPEN-02-2018.
“BRIEFING leverages different ways of exploiting FET research by supporting researchers in their innovation exploration and fostering the connection between the worlds of researchers and different business stakeholder groups.
The BRIEFING portfolio comprises various trainings services for researchers and to-be entrepreneurs from FET Open projects ranging from research communication trainings to innovation opportunity workshops, business trainings as well as matchmaking with industry.”
For Future and Emerging Technologies (FET)/European Innovation Council (EIC) Pathfinder projects a webinar on Innovation and IP Strategy - focus on shared IP in joint research projects - is organized. “The Webinar provides an introduction to the most commonly used IP protection mechanisms and how to use Intellectual Property in a strategic context. In particular, the IP Management approach within the Horizon 2020 framework is discussed as an example for IP in joint research projects.”
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
